136 results on '"De, Arka"'
Search Results
2. Poor Performance of Non-invasive Tests for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: A Multicentric Asian Study
3. Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD
4. Prevalence, Risk Factors, and Impact of Bacterial or Fungal Infections in Acute Liver Failure Patients from India
5. Prevalence of Frailty and Its Impact on Mortality and Hospitalization in Patients With Cirrhosis: A Systematic Review and Meta-analysis
6. Exploring the Prevalence, Predictors, and Impact of Bacterial Infections to Guide Empiric Antimicrobial Decisions in Cirrhosis (EPIC-AD)
7. The “dark” side of terlipressin: a case report of ischemic skin necrosis and review of literature
8. Simple bedside tests of muscle strength and function correlate with computed tomography-skeletal muscle index for assessment of sarcopenia in cirrhosis
9. Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion: A randomized trial
10. Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
11. Association of Heparin-Like Effect, Factor VII/XIII Deficiency and Fibrinolysis with Rebleeding Risk in Cirrhosis with Acute Variceal Bleeding
12. Intravenous BCAA Infusion Does Not Lead to a Sustained Recovery From Overt HE in ACLF – An Open Label Randomized Clinical Trial
13. Burden, risk factors, and outcomes of multidrug-resistant bacterial colonisation at multiple sites in patients with cirrhosis
14. Special Population: Lean Nonalcoholic Fatty Liver Disease
15. INASL–SAASL Consensus Statements on NAFLD Name Change to MAFLD
16. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
17. Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital
18. Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT
19. Hand-grip strength as a screening tool for sarcopenia in males with decompensated cirrhosis
20. Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease
21. Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions
22. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
23. High Prevalence of Hormonal Changes and Hepatic Osteodystrophy in Frail Patients with Cirrhosis—An Observational Study
24. Tuberculosis in Cirrhosis – A Diagnostic and Management Conundrum
25. A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis
26. Myokines are associated with progression, course and mortality in alcohol‐associated liver disease.
27. Prevalence of Acute on Chronic Liver Failure in Autoimmune Hepatitis, Treatment Response and Mortality Burden Assessment: A Region-Predominant Systematic Review and Meta-Analysis.
28. Effectiveness of albumin infusion for the management of hyponatremia in decompensated cirrhosis: a systematic review.
29. Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
30. Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: An analysis of the Indian Consortium on MASLD (ICOM-D) cohort.
31. Crossroad of infection and autoimmunity in acute liver failure: a case report
32. Cholestatic liver injury secondary to over-the-counter cyproheptadine: case report and review of literature.
33. Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study.
34. Growth Hormone Therapy in Decompensated Cirrhosis: An Open-Label, Randomized Control Trial.
35. Cirrhotic cardiomyopathy influences clinical outcomes and enhances performance of conventional risk prediction models in acute‐on‐chronic liver failure with severe sepsis.
36. Endoscopic Ultrasound-Guided Transgastric Shunt Obliteration for Recurrent Hepatic Encephalopathy.
37. Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy.
38. Efficacy, Tolerability, and Compliance of Direct Acting Antivirals in Patients with HIV and Hepatitis C Coinfection: A Real-Life Experience.
39. Assessment of Sarcopenia Using Muscle Ultrasound in Patients With Cirrhosis and Sarcopenic Obesity (AMUSE STUDY).
40. Machine learning can guide suitability of consultation and patient referral through telemedicine for hepatobiliary diseases.
41. Home‐based intensive nutrition therapy improves frailty and sarcopenia in patients with decompensated cirrhosis: A randomized clinical trial.
42. Endoscopic Ultrasound Guided Radiofrequency Ablation for Caudate Lobe Hepatocellular Carcinoma: A New Paradigm in Endohepatology.
43. Tumor infiltrating lymphocytes profile and response in neoadjuvant chemotherapy-treated triple-negative breast carcinoma patients.
44. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
45. Adjuvant Use of Ribavirin with Treatment of Hepatitis C Virus in Kidney Transplant Recipients: A Systematic Review and Meta‑Analysis of Real‑World Data.
46. Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study.
47. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis – Validation in an Indian Cohort.
48. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta‐analysis.
49. Feasibility, Outcomes, and Safety of Telehepatology Services During the COVID‐19 Pandemic.
50. Fingolimod, a sphingosine-1-phosphate agonist for the treatment of hepatopulmonary syndrome: Queries and concerns.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.